Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

This article is part of the supplement: 22nd European Workshop for Rheumatology Research

Open Badges Meeting abstract

Suppression of in vitro and in vivo parameters of inflammatory synovitis by simvastatin

JA Gracie1, D McCarey1, BP Leung1, M Prach1, A Crilly1, SE Robertson1, R Madhok2, JD Young1, FY Liew1, N Sattar1 and IB McInnes1

Author Affiliations

1 University of Glasgow, Glasgow, United Kingdom

2 Centre for Rheumatic Diseases, Glasgow, United Kingdom

For all author emails, please log on.

Arthritis Res 2002, 4(Suppl 1):110  doi:10.1186/ar446

The electronic version of this article is the complete one and can be found online at:

Received:15 January 2002
Published:4 February 2002


Meeting abstract

We have explored in vitro and in vivo the immunomodulatory activities of simvastatin, an HMG Co-A reductase (HMGR) inhibitor, in the context of inflammatory arthritis.


Lymphocyte/monocyte populations were purified from peripheral blood (PB) and synovial fluid/tissues (SF/ST) from rheumatoid arthritis (RA) patients or normal controls as appropriate. Fibroblast-like synoviocytes (FLS) were obtained by serial culture from RAST and utilised from passage 3. T cells were mitogen or cytokine (IL-15) activated then fixed in PFA prior to co-culture with macrophages. Collagen-induced arthritis (CIA) developed in male DBA/1 mice on d26 following priming (d0)/ip challenge (d21) with type II collagen in CFA.


In vitro, simvastatin significantly suppressed macrophage TNFα release following cell contact with cytokine or mitogen activated T cells whether derived from normal or RAPB or from RA SF. Constitutive release of IL-6 by RAFLS was dose dependently suppressed by simvastatin (P < 0.05). In vivo, simvastatin administration (up to 40 mg/kg ip, n = 12/group) from d21 reduced plasma cholesterol by 20% and prevented the development of CIA in a dose dependent manner in comparison with injection of drug vehicle alone (P < 0.01). Ex vivo analysis indicated significant suppression of collagen-specific humoral and cellular immune responses. Moreover, administration of simvastatin (40 mg/kg) significantly suppressed established arthritis (n = 20/group) compared with drug vehicle (P < 0.01).


Simvastatin modulated the release of cell-contact induced proinflammatory cytokines in vitro from cells of RAPB and synovial origin. Both developing and importantly, established CIA were significantly suppressed by administration of simvastatin in vivo. These data demonstrate for the first time the anti-inflammatory, therapeutic potential of HMGR inhibitors in inflammatory arthritis.